McAndrews et al. [169] previously showed that exosomes loaded with CRISPR/Cas9 plasmid DNA could target mutated KRAS G12D in pancreatic cancer cells as well as induce target gene deletion, thereby inhibiting tumor growth in pancreatic cancer homologous subcutaneous and in situ models. The gene discussed is KRAS; the disease is pancreatic neoplasm.